FELBINAC TROMETAMOL

First approved in 2018

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H12O2.C4H11NO3
Molecular Weight	333.3789
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(CO)(CO)CO.OC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2

InChI

InChIKey=SWKYVGAYFCGGRP-UHFFFAOYSA-N

InChI=1S/C14H12O2.C4H11NO3/c15-14(16)10-11-6-8-13(9-7-11)12-4-2-1-3-5-12;5-4(1-6,2-7)3-8/h1-9H,10H2,(H,15,16);6-8H,1-3,5H2

HIDE SMILES / InChI

Molecular Formula	C4H11NO3
Molecular Weight	121.135
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C14H12O2
Molecular Weight	212.2439
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.medicines.org.uk/emc/PIL.29400.latest.pdf | https://www.ncbi.nlm.nih.gov/pubmed/7002162

Felbinac, an active metabolite of fenbufen, is two times more potent than the parent drug. Felbinac is used topically to alleviate pain in the joints and muscles caused by injury or inflammation (Trixam 3% gel or foam). The drug is believed to exert its action by inhibiting COX-2 protein.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Prostaglandin G/H synthase 2 51 Target ID: P35354 Gene ID: 5743.0 Gene Symbol: PTGS2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/7002162	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain in the joints and muscles 2 Sources: https://www.hpra.ie/img/uploaded/swedocuments/2135395.PPA1151_081_001.0b9c827c-5e67-4484-8e8a-21525cc74ebd.000001Product%20Leaflet%20Approved.130823.pdf	Primary		Approved 8583	TRAXAM Approved Use Traxam Gel is used for the relief of pain in the joints and muscles caused by injury or inflammation. It is used for the treatment of the following conditions: sprains, strains, bruising, rheumatic or arthritic conditions, frozen shoulder, tennis elbow or other joint injuries.

C_max

Value	Dose	Analyte	Population
1442 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	11.78 mg single, intravenous dose: 11.78 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2697 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	23.56 mg single, intravenous dose: 23.56 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5772 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	47.13 mg single, intravenous dose: 47.13 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
11947 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	94.25 mg single, intravenous dose: 94.25 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
22043 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	164.92 mg single, intravenous dose: 164.92 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
34889 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	259.16 mg single, intravenous dose: 259.16 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
44879 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	377 mg single, intravenous dose: 377 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5817 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	47.13 mg 1 times / day multiple, intravenous dose: 47.13 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7530 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	47.13 mg 3 times / day multiple, intravenous dose: 47.13 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
11474 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	94.25 mg 1 times / day multiple, intravenous dose: 94.25 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
13568 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	94.25 mg 3 times / day multiple, intravenous dose: 94.25 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
21230 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	188.5 mg 1 times / day multiple, intravenous dose: 188.5 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
26473 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	188.5 mg 3 times / day multiple, intravenous dose: 188.5 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
5.6 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	11.78 mg single, intravenous dose: 11.78 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10.7 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	23.56 mg single, intravenous dose: 23.56 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
22.2 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	47.13 mg single, intravenous dose: 47.13 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
54 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	94.25 mg single, intravenous dose: 94.25 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
96 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	164.92 mg single, intravenous dose: 164.92 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
119 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	259.16 mg single, intravenous dose: 259.16 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
182 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	377 mg single, intravenous dose: 377 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
18 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	47.13 mg 1 times / day multiple, intravenous dose: 47.13 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
28 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	47.13 mg 3 times / day multiple, intravenous dose: 47.13 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
35 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	94.25 mg 1 times / day multiple, intravenous dose: 94.25 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
48 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	94.25 mg 3 times / day multiple, intravenous dose: 94.25 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
65 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	188.5 mg 1 times / day multiple, intravenous dose: 188.5 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
95 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	188.5 mg 3 times / day multiple, intravenous dose: 188.5 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
4.25 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	11.78 mg single, intravenous dose: 11.78 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5.18 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	23.56 mg single, intravenous dose: 23.56 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	47.13 mg single, intravenous dose: 47.13 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.24 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	94.25 mg single, intravenous dose: 94.25 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5.46 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	164.92 mg single, intravenous dose: 164.92 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5.46 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	259.16 mg single, intravenous dose: 259.16 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5.83 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	377 mg single, intravenous dose: 377 mg route of administration: Intravenous experiment type: SINGLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	47.13 mg 1 times / day multiple, intravenous dose: 47.13 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.59 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	47.13 mg 3 times / day multiple, intravenous dose: 47.13 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5.79 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	94.25 mg 1 times / day multiple, intravenous dose: 94.25 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	94.25 mg 3 times / day multiple, intravenous dose: 94.25 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5.71 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	188.5 mg 1 times / day multiple, intravenous dose: 188.5 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7.38 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32700191/	188.5 mg 3 times / day multiple, intravenous dose: 188.5 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	FELBINAC plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
1 g 2 times / day multiple, topical Recommended Dose: 1 g, 2 times / day Route: topical Route: multiple Dose: 1 g, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1519685/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/1519685/	Sources: https://pubmed.ncbi.nlm.nih.gov/1519685/
1 g 4 times / day multiple, topical Recommended Dose: 1 g, 4 times / day Route: topical Route: multiple Dose: 1 g, 4 times / day Sources: https://www.medicines.org.uk/emc/product/3422/smpc#CLINICAL_PRECAUTIONS	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.medicines.org.uk/emc/product/3422/smpc#CLINICAL_PRECAUTIONS	Disc. AE: Rash... AEs leading to discontinuation/dose reduction: Rash Sources: https://www.medicines.org.uk/emc/product/3422/smpc#CLINICAL_PRECAUTIONS

AEs

AE	Significance	Dose	Population
Rash	Disc. AE	1 g 4 times / day multiple, topical Recommended Dose: 1 g, 4 times / day Route: topical Route: multiple Dose: 1 g, 4 times / day Sources: https://www.medicines.org.uk/emc/product/3422/smpc#CLINICAL_PRECAUTIONS	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.medicines.org.uk/emc/product/3422/smpc#CLINICAL_PRECAUTIONS

PubMed

Title	Date	PubMed
Topical nonsteroidal anti-inflammatory drugs for the treatment of pain due to soft tissue injury: diclofenac epolamine topical patch.	2010-11-10	21197326
2-(Biphenyl-4-yl)acetic acid (felbinac).	2010-09-25	21587585
Design, synthesis and evaluation of mutual prodrug of 4-biphenylacetic acid and quercetin tetramethyl ether (BPA-QTME) as gastrosparing NSAID.	2010-06	20227799
The suitability of tris(hydroxylmethyl) aminomethane (THAM) as a buffering system for hydroxypropyl methylcellulose (HPMC) hydrophilic matrices containing a weak acid drug.	2010-03-15	20005935
Incorporating multiple interventions in meta-analysis: an evaluation of the mixed treatment comparison with the adjusted indirect comparison.	2009-09-21	19772573
Validated LC-MS/MS assay for the determination of felbinac: Application to a preclinical pharmacokinetics study of felbinac trometamol injection in rat.	2009-08-15	19376665
Separation-oriented derivatization of native fluorescent compounds through fluorous labeling followed by liquid chromatography with fluorous-phase.	2009-06-15	19459682
Mechanisms of drug release in citrate buffered HPMC matrices.	2009-03-31	19100822
Cyclomaltoheptaose mixed esters of anti-inflammatory drugs and short-chain fatty acids and study of their enzymatic hydrolysis in vitro.	2009-03-10	19185291
Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents.	2009	19430173
Stepwise two-color laser photolysis studies of alpha-cleavage in highly excited triplet states of alpha-acyl-4-phenylphenols.	2008-06	18528556
Analgesic effect of percutaneously absorbed non-steroidal anti-inflammatory drugs: an experimental study in a rat acute inflammation model.	2008-01-31	18234123
Percutaneous penetration of felbinac after application of transdermal patches: relationship with pharmacological effects in rats.	2008-01	18088507
Synthesis and pharmacological evaluation of some dual-acting amino-alcohol ester derivatives of flurbiprofen and 2-[1,1'-biphenyl-4-yl]acetic acid: a potential approach to reduce local gastrointestinal toxicity.	2006-11	17193237
Changes in brain interleukin-1beta following the coadministration of norfloxacin with biphenylacetic acid in rats.	2006-08-14	16824509
Pharmaceutical quality control of acid and neutral drugs based on competitive self-assembly in amphiphilic systems.	2006-01	16365667
Gastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylation.	2004-07-02	15117964
Topical NSAIDs for acute pain: a meta-analysis.	2004-05-17	15147585
Synthetic applications of o- and p-halobenzyl sulfones as zwitterionic synthons: preparation of ortho-substituted cinnamates and biarylacetic acids.	2002-07-26	12126409
Estimation of intradermal disposition kinetics of drugs: II. Factors determining penetration of drugs from viable skin to muscular layer.	2002-06-04	12052698
[Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].	2002-06	12199111
Intercalation and controlled release of pharmaceutically active compounds from a layered double hydroxide.	2001-11-21	12240066
Inhibitory effect of quinolone antimicrobial and nonsteroidal anti-inflammatory drugs on a medium chain acyl-CoA synthetase.	2001-08-01	11434910
Effects of amino acids on the amidation of polyaromatic carboxylic acids by Bacillus cereus.	2001-08	11577715
Topical non-steroidal drugs are systemically absorbed and may cause renal disease.	1999-01	10052505
Role of nitric oxide in the convulsive seizures induced by fluoroquinolones coadministered with 4-biphenyl acetic acid.	1997-11	9347323
Quantitation of GABAA receptor inhibition required for quinolone-induced convulsions in mice.	1994-11	7706169
Biphenylacetate, but not theophylline, lethally interacts with ciprofloxacin in mice.	1993-11	8115312
Involvement of inhibitory and excitatory neurotransmitters in levofloxacin- and ciprofloxacin-induced convulsions in mice.	1993-09	7902066

Patents

Sample Use Guides

In Vivo Use Guide

The usual dose is about one inch or 2.5cm (which is about one gram) of gel rubbed into the affected area two to four times a day.

Route of Administration: Topical

In Vitro Use Guide

A 0.12 mM concentration of felbinac (BPAA) produces almost complete inhibition of arachidonate-induced aggregation of blood platelets.

Substance Class	Chemical Created by `admin` on `Tue Apr 01 21:55:52 GMT 2025` Edited by `admin` on `Tue Apr 01 21:55:52 GMT 2025`
Record UNII	HA8ZX3VG09
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

(1,1'-BIPHENYL)-4-ACETIC ACID, COMPD. WITH 2-AMINO-2-(HYDROXYMETHYL)-1,3-PROPANEDIOL (1:1)

Preferred Name

English

FELBINAC TROMETAMOL

Common Name

English

Code System Code Type Description

CAS

935886-64-9

Created by admin on Tue Apr 01 21:55:52 GMT 2025 , Edited by admin on Tue Apr 01 21:55:52 GMT 2025

PRIMARY

PUBCHEM

44238058

Created by admin on Tue Apr 01 21:55:52 GMT 2025 , Edited by admin on Tue Apr 01 21:55:52 GMT 2025

PRIMARY

FDA UNII

HA8ZX3VG09

Created by admin on Tue Apr 01 21:55:52 GMT 2025 , Edited by admin on Tue Apr 01 21:55:52 GMT 2025

PRIMARY

Related Record Type Details


					94WNJ5U8L7

FELBINAC

PARENT -> SALT/SOLVATE

Amount:

Related Record Type Details


					94WNJ5U8L7

FELBINAC

ACTIVE MOIETY

Amount:

Details

SMILES

InChI

DescriptionSources: http://www.medicines.org.uk/emc/PIL.29400.latest.pdf | https://www.ncbi.nlm.nih.gov/pubmed/7002162

Approval Year

Targets

Conditions

Approved Use

Cmax

AUC

T1/2

Doses

AEs

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.medicines.org.uk/emc/PIL.29400.latest.pdf | https://www.ncbi.nlm.nih.gov/pubmed/7002162

C_max

T_1/2